Parag V. Meswani
Corporate Officer/Principal bei ACADIA PHARMACEUTICALS INC.
Profil
Parag V.
Meswani is currently the Senior Vice President-Trofinetide at ACADIA Pharmaceuticals, Inc. Prior to this, he held positions at Biogen, Inc. as the Chief Executive Officer-Commercial Operations, at Spark Therapeutics, Inc. as the Head-US Marketing, and at Sio Gene Therapies, Inc. as the Chief Commercial Officer.
Dr. Meswani has an MBA from The Trustees of Columbia University in The City of New York, an undergraduate and doctorate degree from Ernest Mario School of Pharmacy, and another MBA from Columbia Business School.
Aktive Positionen von Parag V. Meswani
| Unternehmen | Position | Beginn |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01.04.2022 |
Ehemalige bekannte Positionen von Parag V. Meswani
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | Geschäftsführer | 06.10.2020 |
| BIOGEN INC. | Corporate Officer/Principal | - |
| SPARK THERAPEUTICS, INC. | Vertrieb & Marketing | - |
Ausbildung von Parag V. Meswani
| Ernest Mario School of Pharmacy | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
